Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. SPY
6. BLZE
7. IBM
8. NKE
9. MU
10. ACN

Go back to Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition

Eli Lilly & Co. (LLY) Tops Q4 EPS by 21c, Updates FY Guidance

January 30, 2020 6:28 AM EST

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $1.73, $0.21 better than the analyst estimate of $1.52. Revenue for the quarter came in at $6.11 billion versus the consensus estimate of $5.91 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2020 EPS of $6.70-$6.80, versus... More